<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615221</url>
  </required_header>
  <id_info>
    <org_study_id>2019_0059</org_study_id>
    <nct_id>NCT04615221</nct_id>
  </id_info>
  <brief_title>Immunological Mechanisms of Rejection in Uterine Transplantation</brief_title>
  <acronym>MARNI</acronym>
  <official_title>Immunological Mechanisms of Rejection in Uterine Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to understand the mechanisms of rejection in uterine&#xD;
      transplantation and to search for non-invasive markers of rejection. The biological samples&#xD;
      necessary for our research have been or will be collected during procedures (biopsies,&#xD;
      smears, vaginal swab, blood tests) carried out as part of the scheduled follow-up of&#xD;
      patients. These will be samples whose collection is minimally or not invasive&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the context of uterine transplantation, non-invasive rejection markers will be sought by&#xD;
      different approaches, including transcriptomics on a prospective cohort of patients with&#xD;
      different types of samples: blood, smear and biopsy. A microbiota study will also be carried&#xD;
      out. 3 groups will be studied: 1 group of 10 patients benefiting or having benefited from a&#xD;
      uterine transplant, 1 second group made up of their 10 donors, 1 group of 10 control women&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence of new markers associated with transplant rejection</measure>
    <time_frame>8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of pregnancy on transplant immunology</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbiota in uterine transplant</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Graft recipient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During each of the visits carried out with a cervical biopsy as part of the uterine transplant project, samples will be taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Living donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The donors will benefit from a blood sample and a sample of the vaginal microbiota during the transplant under general anesthesia or after it during a consultation scheduled as part of the uterine transplant protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Witness</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 non-menopausal control patients will each have a cervical biopsy (at different times of the cycle) and a smear, samples of the vaginal microbiota and a blood sample. Among the 10 controls, 4 patients will have to undergo a hysterectomy for which multiple staged biopsies and samples uterine microbiota will be produced.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Specimens</intervention_name>
    <description>Specimens (blood, biopsy, cervical smear, vaginal swab)</description>
    <arm_group_label>Graft recipient</arm_group_label>
    <arm_group_label>Living donor</arm_group_label>
    <arm_group_label>Witness</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient going to or having received a uterine transplant OR Patient going to or having&#xD;
             donated a uterus for a recipient included in the study OR Premenopausal woman to&#xD;
             undergo gynecological surgery under general anesthesia: for 4 of them it was a&#xD;
             hysterectomy and they must be under 45 years old, the other 6 must be under 38 years&#xD;
             old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For witness&#xD;
&#xD;
          -  Pregnancy in progress&#xD;
&#xD;
          -  Current infection&#xD;
&#xD;
          -  Cervical dysplasia&#xD;
&#xD;
          -  History of transplant or transfusion&#xD;
&#xD;
          -  Cancer or history of cancer&#xD;
&#xD;
          -  Menopause&#xD;
&#xD;
          -  Patient aged 38 or over for the 6 controls without hysterectomy, patient aged 45 or&#xD;
             over for the 4 patients with hysterectomy.&#xD;
&#xD;
          -  Endometriosis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Ayoubi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Foch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Carbonnel, MD</last_name>
    <phone>+331 46 25 48 53</phone>
    <email>m.carbonnel@hopital-foch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Hulier-Ammar</last_name>
    <phone>+331 46 25 11 75</phone>
    <email>drci-promotion@hopital-foch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Carbonnel</last_name>
      <email>m.carbonnel@hopital-foch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

